Cargando…
Chromogranin A, a significant prognostic factor in small cell lung cancer
Chromogranin A (CgA) is a protein present in neuroendocrine vesicles. Small cell lung cancer (SCLC) is considered a neuroendocrine tumour. It is possible to demonstrate CgA expression in SCLC by immunohistochemical methods. Since CgA is released to the circulation it might also work as a clinical tu...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362890/ https://www.ncbi.nlm.nih.gov/pubmed/10574253 http://dx.doi.org/10.1038/sj.bjc.6690745 |
_version_ | 1782153566881841152 |
---|---|
author | Drivsholm, L Paloheimo, L I Østerlind, K |
author_facet | Drivsholm, L Paloheimo, L I Østerlind, K |
author_sort | Drivsholm, L |
collection | PubMed |
description | Chromogranin A (CgA) is a protein present in neuroendocrine vesicles. Small cell lung cancer (SCLC) is considered a neuroendocrine tumour. It is possible to demonstrate CgA expression in SCLC by immunohistochemical methods. Since CgA is released to the circulation it might also work as a clinical tumour marker. We used a newly developed two-site enzyme-linked immunosorbent assay for CgA in plasma from 150 newly diagnosed patients with SCLC. Follow-up was for a minimum of 5 years. Thirty-seven per cent of the patients had elevated pretreatment values and the values were significantly related to stage of disease. Multivariable analysis by Cox's proportional hazard model including nine known prognostic factors disclosed performance status as the most influential prognostic factor followed by stage of disease, CgA and LDH. A simple prognostic index (PI) could be established based on these four pretreatment features. In this way the patients could be separated into three groups with significant different prognosis. The median survival and 95% confidence intervals for the three groups were as follows: 424 days (311–537), 360 days (261–459) and 174 days (105–243). © 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2362890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23628902009-09-10 Chromogranin A, a significant prognostic factor in small cell lung cancer Drivsholm, L Paloheimo, L I Østerlind, K Br J Cancer Regular Article Chromogranin A (CgA) is a protein present in neuroendocrine vesicles. Small cell lung cancer (SCLC) is considered a neuroendocrine tumour. It is possible to demonstrate CgA expression in SCLC by immunohistochemical methods. Since CgA is released to the circulation it might also work as a clinical tumour marker. We used a newly developed two-site enzyme-linked immunosorbent assay for CgA in plasma from 150 newly diagnosed patients with SCLC. Follow-up was for a minimum of 5 years. Thirty-seven per cent of the patients had elevated pretreatment values and the values were significantly related to stage of disease. Multivariable analysis by Cox's proportional hazard model including nine known prognostic factors disclosed performance status as the most influential prognostic factor followed by stage of disease, CgA and LDH. A simple prognostic index (PI) could be established based on these four pretreatment features. In this way the patients could be separated into three groups with significant different prognosis. The median survival and 95% confidence intervals for the three groups were as follows: 424 days (311–537), 360 days (261–459) and 174 days (105–243). © 1999 Cancer Research Campaign Nature Publishing Group 1999-10 /pmc/articles/PMC2362890/ /pubmed/10574253 http://dx.doi.org/10.1038/sj.bjc.6690745 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Drivsholm, L Paloheimo, L I Østerlind, K Chromogranin A, a significant prognostic factor in small cell lung cancer |
title | Chromogranin A, a significant prognostic factor in small cell lung cancer |
title_full | Chromogranin A, a significant prognostic factor in small cell lung cancer |
title_fullStr | Chromogranin A, a significant prognostic factor in small cell lung cancer |
title_full_unstemmed | Chromogranin A, a significant prognostic factor in small cell lung cancer |
title_short | Chromogranin A, a significant prognostic factor in small cell lung cancer |
title_sort | chromogranin a, a significant prognostic factor in small cell lung cancer |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362890/ https://www.ncbi.nlm.nih.gov/pubmed/10574253 http://dx.doi.org/10.1038/sj.bjc.6690745 |
work_keys_str_mv | AT drivsholml chromograninaasignificantprognosticfactorinsmallcelllungcancer AT paloheimoli chromograninaasignificantprognosticfactorinsmallcelllungcancer AT østerlindk chromograninaasignificantprognosticfactorinsmallcelllungcancer |